The end of the Ozempic and semaglutide commercial exclusivity It marks a turning point in the pharmacological treatment of obesity and type 2 diabetes. What until now was an expensive drug, accessible mainly to those who could afford very high prices, is beginning to become a much more widespread product thanks to the introduction of generic versions.
Although Europe and the United States will maintain patent protection By the early 2030s, the expiration of patents in other territories is already triggering a profound shift in the global market. Countries with powerful generic drug industries, such as India and China, are preparing to flood their domestic markets with licensed copies and, eventually, supply much of the rest of the world as well.
What does it mean that Ozempic's patent is ending?
The drug known commercially as Ozempic, and its obesity version Wegovy, share the same active ingredient: semaglutide, a GLP-1 receptor agonist It mimics a hormone responsible for regulating appetite and blood glucose. For years, Novo Nordisk has enjoyed a global monopoly in major markets thanks to the protection of its patents.
When a pharmaceutical patent expiresOther companies can manufacture and sell medicines that contain the same active ingredient, at the same dose, and with equivalent efficacy. These are called generics, which must pass regulatory controls to demonstrate quality, safety, and bioequivalence, but they start with a key advantage: they do not have to recoup the initial investment in research and clinical trials.
In the case of semaglutide, the end of the patent begins in stages. Canada was one of the first countries to see the protection expire.Although copies have not yet been authorized there, in India the expiration date has unlocked the possibility of registering and marketing the first generics this year.
Meanwhile, in territories such as the European Union or the United States, the combination of basic patents and regulatory extensions It keeps the market protected for Novo Nordisk until approximately 2030, delaying the arrival of cheaper alternatives for European patients by several years.
India takes the lead with a flood of generics
The first major shock to Ozempic's monopoly is coming from India, considered the “pharmacy of the world” because of its enormous generic drug industry. The expiration of the semaglutide patent in this country has allowed a good number of local laboratories to make their move immediately.
Large Indian pharmaceutical companies such as Cipla, Sun Pharma, Dr. Reddy's, Biocon, Natco, Zydus, Mankind Pharma or Alkem Companies have already applied for regulatory approval to launch their own injectable or oral versions of semaglutide. Some, like Zydus Lifesciences, have announced launches virtually from "Day 1," with the intention of having product available immediately.
Analysts estimate that More than 40 local manufacturers could appear Offering around 50 different brands of generic semaglutide within a few weeks. This is a common pattern in the Indian market: when the patent for the antidiabetic drug sitagliptin expired, some 30 presentations arrived in the first month and nearly 100 within a year.
This competitive pressure comes at a complex health time. India is grappling with significant rates of malnutrition and, at the same time, a rapid increase in overweight and obesityDriven by urbanization, high-carbohydrate diets, and increased sedentary lifestyles, the country is estimated to have over 77 million people with type 2 diabetes and a high proportion of overweight adults.
For many Indian doctors, having access to GLP-1 agonists at lower prices This represents adding a powerful tool to their arsenal for tackling two simultaneous epidemics: obesity and diabetes. Endocrinologists, cardiologists, orthopedic surgeons, and pulmonologists already use these drugs to reduce weight before procedures or to improve problems such as sleep apnea.
Price drop: from luxury treatment to mass-market option
The most immediate effect of the end of Ozempic's patent in India and other countries is the expected price collapseWhile, under brand name, a month's treatment with Ozempic or Wegovy could cost between $95 and $180 in India, forecasts point to a completely different scenario with generics.
Local firms like Natco Pharma have announced price ranges: they plan to sell Semaglutide injections cost around $14 per month For the most basic doses, prices are around $48 for multi-purpose "pen"-type formats. Other producers are considering starting prices between $30 and $60 per month, with room for further reductions if competition intensifies.
Some studies and consultancies go even further and estimate that, with optimized production and high volumes, It would be possible to mass-produce semaglutide for about $3 per month per patient in low- and middle-income countries where patent protection was never sought or granted. This figure, in theory, opens the door for the healthcare systems of those countries to potentially finance the treatment more broadly.
When compared to markets like the United States, the contrast is striking: High doses of Wegovy without coverage can cost around $300-$350 per month.And some treatments cost over $900 or even $1.300, depending on the regimen and insurance. In this context, a generic drug costing $15-$50 in emerging countries would represent a significant price difference.
The Indian experience also suggests possible effects elsewhere. The same reliance on generic competition was key in the past to drastically reduce the cost of antiretroviral drugs against HIVwhich went from being inaccessible to becoming affordable treatments for millions of patients in Africa and Asia thanks to mass production in India.
What is happening in Europe and Spain in the meantime?
The map is not homogeneous. Although by 2026 the Key patents for semaglutide will have expired in a dozen countries which account for around 40-48% of the global burden of obesity (including India, China, Brazil, South Africa, Turkey or Canada), the reality is different in the so-called "Global North".
En the European Union and the United StatesNovo Nordisk has patent protection extensions based on regulations designed to incentivize pharmaceutical innovation. These rules allow for extending commercial exclusivity for several years beyond the theoretical 20-year patent term, compensating for the time invested in clinical trials and regulatory procedures.
In practice, this means that in Europe, and therefore in countries like Spain, The legal entry of generic semaglutide is not expected until the beginning of the next decade.Until then, Ozempic and Wegovy will remain subject to the classic patent model, with high prices and access conditioned by the funding decisions of each national health system.
European healthcare services already cover semaglutide for Indication for type 2 diabetes in certain clinical profilesHowever, regulations tend to be much more restrictive when the use is solely for weight loss. The current cost limits its widespread funding as an obesity treatment, despite the magnitude of the problem: the WHO estimates that more than 1.000 billion people worldwide live with obesity, and the trend in Europe is on the rise.
In this scenario, the deployment of generic drugs in other continents may exert some indirect pressure. In the medium term, the existence of mass production and very low prices in countries where no patent exists could be a factor. This could serve as an argument for renegotiating prices in Europe as the expiration date approaches. Furthermore, it is possible that some patients may attempt to import the medication from jurisdictions where it is cheaper, although European and Spanish regulations are restrictive and these channels are usually highly controlled.
Global impact on public health and industry
The gradual end of Ozempic's protection comes at a time when Obesity has become established as one of the major health challenges. This is true in both wealthy countries and emerging economies. Rates have doubled in adults since 1990 and quadrupled in children and adolescents, multiplying the risk of diabetes, cardiovascular disease, and certain cancers.
In this context, semaglutide-based drugs have been described as a “turning point” by many specialists. Clinical trial data show significant weight loss and improved glucose controlIn addition to added benefits in cardiovascular events in certain high-risk profiles. However, experts insist that they are not a magic bullet: they require following a proper diet and increase physical activity to avoid, for example, excessive loss of muscle mass.
At market scale, the emergence of generics threatens to reorganize the diabetes and obesity drug businessNovo Nordisk and Eli Lilly have experienced unprecedented sales growth, with Ozempic, Wegovy, Mounjaro, and Zepbound becoming bestsellers. Now, the loss of exclusivity in densely populated countries is reducing revenue expectations and forcing these companies to rethink pricing and strategies.
Novo Nordisk's response has been multifaceted. On the one hand, He has litigated in courts in India, China, and Brazil. to try to curb or delay the entry of generics. On the other hand, it has resorted to selective price reductions in some key markets and to position its branded product as a "premium" option compared to cheaper copies.
Meanwhile, both Novo Nordisk and Eli Lilly are accelerating development of new generations of drugsincluding oral formulations and molecules with combined mechanisms of action, with the aim of maintaining their competitive advantage when semaglutide becomes a mature product plagued by generics.
Risks, side effects and the need for monitoring
The expansion of these treatments is not without its drawbacks. GLP-1 agonists like semaglutide are potent, but may cause adverse effects such as nausea, vomiting, diarrhea, constipation or abdominal discomfort, especially at the start of treatment or if the dose is increased too quickly.
To a lesser extent, clinical reports and pharmacovigilance have described more serious but rare complicationsSide effects include pancreatitis, gallbladder problems, or significant muscle loss when the medication is not combined with a high-protein diet and strength training. Furthermore, a "weight rebound" phenomenon is frequently observed upon discontinuation of treatment: appetite returns strongly, and the body tends to regain some of the lost fat.
With the decrease in the cost of copies, doctors fear a increasingly widespread use without proper supervisionIn countries where generic drugs are becoming more widespread, cases have been detected of high doses being prescribed or recommended by gyms, aesthetic clinics, or professionals without the necessary training. Sales through online pharmacies following only superficial consultations have also been reported.
Regulators in India, for example, have issued circulars reminding that Direct-to-consumer advertising of prescription drugs It's not allowed, and authorities have warned about campaigns promising dramatic weight loss without mentioning the need for diet and exercise. They are trying to curb enthusiasm fueled by social media and celebrity endorsements.
Internists and endocrinologists insist that the Patient selection is keyIt's not enough to simply look at body mass index; it's also necessary to assess whether diabetes, hypertension, high cholesterol, or other risk factors are present. Furthermore, they recommend introducing the medication only after implementing lifestyle changes and clearly explaining what to expect and how long medication might need to be maintained.
The role of India and China in global supply
The loss of patents in countries with significant industrial capacity has another important consequence: the ability to export generic semaglutide to markets where there is no patent protection or where regulatory frameworks allow it. India already supplies more than half of the generic drugs consumed in Africa and a very significant portion of those used in the United States and the United Kingdom.
The country's reputation as a provider of affordable medicines was built precisely on success stories in antiretrovirals, antibiotics or cancer treatmentsWith semaglutide, history could repeat itself: a drug initially restricted to affluent sectors would become integrated into the therapeutic arsenals of many low- and middle-income health systems.
China, for its part, already hosts numerous manufacturers of semaglutide active ingredients which supply various markets, including compounded medications in the United States. Several Chinese laboratories are in advanced stages of evaluating the commercialization of their own generic diabetes drugs, which will add to the global supply in the short term.
For European authorities and for countries like Spain, this external scenario also raises questions about how will they integrate generic futures into their funding policies When the time comes. Experience with other medications suggests that the introduction of generics is usually accompanied by price revisions, updated clinical guidelines, and, in many cases, expanded coverage for more patients.
In any case, regulatory agencies should pay particular attention to the quality of the new formulationsThe manufacture of peptides such as semaglutide is technically complex, and both doctors and health authorities stress the importance of not compromising safety in exchange for lower cost.
The combination of the progressive expiration of Ozempic's patent, the powerful generics industry in countries like India and China, and the global magnitude of obesity and diabetes paints a picture of a rapidly transforming scenario: semaglutide-based treatments tend to become much more accessible in much of the world, while Europe and Spain await their turn, tied to a longer patent schedule, with the challenge of taking advantage of future price reductions without losing sight of safety, rational prescription, and the need to maintain a focus on lifestyle changes, which remain the foundation of the obesity approach.
